



Press release 2015-10-12

C-RAD signs sales and distribution agreement with GE Healthcare

GE Healthcare has entered into a sales and distribution agreement for C-RAD's Sentinel 4DCT™ systems and Cyrpa High Impact Technology (HIT) laser systems. These systems are used for 4D imaging and virtual simulation in radiation therapy. GE will offer these solutions through its price book, making them available to the GE salesforce and their customers worldwide.

A special logistic system – C-RAD Smart Logistics™ – has been developed and is currently being implemented. This system optimizes the logistic processes and simplifies the supply chain for C-RAD's distributors. With its global footprint, C-RAD will therefore be able to launch distribution hubs in Europe, the US and Asia to provide more rapid deliveries. This model could be attractive for other OEM customers in the medtech industry.

It is expected that C-RAD and Cyrpa products will be included in GE's price book during the fourth quarter. First orders are expected during the first quarter of 2016. C-RAD will be ready to deliver from January 2016 on.

The worldwide market for advanced CTs sold into radiation therapy is about 400 units a year. The large majority is delivered with a laser system for virtual simulation. In advanced markets the proportion of CTs that is delivered with 4D imaging is rapidly growing.

C-RAD has hired a dedicated key account manager to support our distributors and to develop distribution through this sales channel.

“This new agreement with GE represents an interesting strategic opportunity for us,” says Tim Thurn, CEO of C-RAD. “C-RAD has an appealing product portfolio, and it is our intention to make our distributors' product offerings even more attractive. At the same time C-RAD can benefit from the strong presence of the sales and distribution organizations of OEM distributors.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 39. C-RAD's business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in



China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).